Biosolutions Clinical Research Center LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$5,414	2
2024	Research	$97,411	2
2023	Research	$86,219	4
2022	Research	$108,335	18
2021	Research	$11,434	1

Breakdown

Who paid Research payments · program years 2021–2025

Novartis Pharmaceuticals Corporation $209,036 10 payments
Endo Pharmaceuticals Inc. $99,777 17 payments

Studies the money was for Research payments · program years 2021–2025

A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy $150,970 6 payments
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis $75,761 13 payments
A Randomized, Two-Arm, Placebo-Controlled, Participant and Investigator-Blinded Study Investigating the Efficacy, Safety and Tolerability of Dfv890 in Patients With Symptomatic Knee Osteoarthritis $58,066 4 payments
A Multi-Center, Open-Label, Extension Study to Evaluate the Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis $24,016 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.